DK0681483T3 - Præparater og fremgangsmåder til administration af genetisk materiale - Google Patents
Præparater og fremgangsmåder til administration af genetisk materialeInfo
- Publication number
- DK0681483T3 DK0681483T3 DK94909492T DK94909492T DK0681483T3 DK 0681483 T3 DK0681483 T3 DK 0681483T3 DK 94909492 T DK94909492 T DK 94909492T DK 94909492 T DK94909492 T DK 94909492T DK 0681483 T3 DK0681483 T3 DK 0681483T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- individual
- protein
- disclosed
- cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US834293A | 1993-01-26 | 1993-01-26 | |
US2933693A | 1993-03-11 | 1993-03-11 | |
US9323593A | 1993-07-15 | 1993-07-15 | |
US12496293A | 1993-09-21 | 1993-09-21 | |
US08/125,012 US5593972A (en) | 1993-01-26 | 1993-09-21 | Genetic immunization |
US08/979,385 US5981505A (en) | 1993-01-26 | 1994-01-26 | Compositions and methods for delivery of genetic material |
US49568495A | 1995-08-28 | 1995-08-28 | |
US09/359,975 US7001759B1 (en) | 1993-01-26 | 1999-07-23 | Compositions and methods for delivery of genetic material |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0681483T3 true DK0681483T3 (da) | 2005-11-21 |
Family
ID=38247352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94909492T DK0681483T3 (da) | 1993-01-26 | 1994-01-26 | Præparater og fremgangsmåder til administration af genetisk materiale |
Country Status (14)
Country | Link |
---|---|
US (1) | US8304234B2 (da) |
EP (1) | EP0681483B1 (da) |
JP (1) | JP3701966B2 (da) |
AT (1) | ATE302854T1 (da) |
AU (1) | AU675702B2 (da) |
CA (1) | CA2153593C (da) |
DE (1) | DE69434469T2 (da) |
DK (1) | DK0681483T3 (da) |
ES (1) | ES2249760T3 (da) |
HU (1) | HU219767B (da) |
IL (1) | IL108449A (da) |
NZ (1) | NZ262582A (da) |
PT (1) | PT681483E (da) |
WO (1) | WO1994016737A1 (da) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09501936A (ja) * | 1993-08-26 | 1997-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置 |
US6348449B1 (en) | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
US6235888B1 (en) | 1994-10-05 | 2001-05-22 | The General Hospital Corporation | Hepatitis C virus vaccine |
RU2189254C2 (ru) * | 1995-06-06 | 2002-09-20 | Америкэн Хоум Продактс Корпорэйшн | Вакцины против вирусов гепатита |
USRE38490E1 (en) | 1995-11-16 | 2004-04-06 | Baylor College Of Medicine | Method for identifying metastatic sequences |
EP0923284A4 (en) * | 1996-01-19 | 2003-03-26 | Allegheny University Of The He | CELLULAR IMMUNOGENES THAT ARE USEFUL AS A VACCINE AGAINST CANCER |
USRE38392E1 (en) | 1996-01-30 | 2004-01-20 | Baylor College Of Medicine | Method for identifying metastatic sequences |
US6168918B1 (en) | 1996-01-31 | 2001-01-02 | American Home Products Corp. | Method of detecting foreign DNA integrated in eukaryotic chromosomes |
US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
DE69734585T2 (de) * | 1996-02-22 | 2006-08-10 | Merck & Co., Inc. | Synthetische hiv-gene |
US5851804A (en) * | 1996-05-06 | 1998-12-22 | Apollon, Inc. | Chimeric kanamycin resistance gene |
US7235056B2 (en) | 1996-05-17 | 2007-06-26 | Amira Medical | Body fluid sampling device and methods of use |
US20020010406A1 (en) | 1996-05-17 | 2002-01-24 | Douglas Joel S. | Methods and apparatus for expressing body fluid from an incision |
EP1579814A3 (en) | 1996-05-17 | 2006-06-14 | Roche Diagnostics Operations, Inc. | Methods and apparatus for sampling and analyzing body fluid |
US7828749B2 (en) | 1996-05-17 | 2010-11-09 | Roche Diagnostics Operations, Inc. | Blood and interstitial fluid sampling device |
US7666150B2 (en) | 1996-05-17 | 2010-02-23 | Roche Diagnostics Operations, Inc. | Blood and interstitial fluid sampling device |
US5846946A (en) * | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
CA2258568A1 (en) * | 1996-06-21 | 1997-12-24 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
KR100564268B1 (ko) * | 1996-10-23 | 2006-03-27 | 와이어쓰 | 백신 |
US6228621B1 (en) * | 1996-10-23 | 2001-05-08 | The Trustees Of The University Of Pennsylvania | Plasmids encoding immunogenic proteins and intracellular targeting sequences |
CN1238807A (zh) * | 1996-11-01 | 1999-12-15 | 基因观测公司 | 稳定的瞬时基因表达 |
US6146847A (en) * | 1996-11-01 | 2000-11-14 | Genespan Corporation | Stabilized transient gene expression |
WO1998024912A2 (en) * | 1996-12-04 | 1998-06-11 | Heska Corporation | Recombinant plague vaccine |
GB9626539D0 (en) * | 1996-12-20 | 1997-02-05 | Univ Liverpool | A method of enhancing the rate of transfection of cells |
US6696291B2 (en) | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
AU743616B2 (en) * | 1997-02-07 | 2002-01-31 | Merck & Co., Inc. | Synthetic HIV gag genes |
US6217900B1 (en) * | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
EP1006999A2 (en) * | 1997-07-08 | 2000-06-14 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
US6818627B1 (en) | 1997-08-14 | 2004-11-16 | The Trustees Of The University Of Pennsylvania | Functional fragments of HIV-1 Vpr protein and methods of using the same |
ES2389519T3 (es) | 1997-09-18 | 2012-10-26 | The Trustees Of The University Of Pennsylvania | Casetes de inmunización de ADN de vif atenuados para vacunas genéticas |
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
WO1999021591A1 (en) | 1997-10-28 | 1999-05-06 | American Home Products Corporation | Compositions and methods for delivery of genetic material |
CA2308565A1 (en) | 1997-11-05 | 1999-05-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
CN101126094A (zh) * | 1998-01-30 | 2008-02-20 | 总医院有限公司 | 采用丙型肝炎病毒非结构蛋白进行的基因免疫 |
WO1999046385A2 (en) | 1998-03-13 | 1999-09-16 | Baylor College Of Medicine | Compositions and methods for the treatment and prevention of metastatic disorders |
AU5366099A (en) | 1998-08-20 | 2000-03-14 | Connaught Laboratories Limited | Nucleic acid molecules encoding inclusion membrane protein of (chlamydia) |
US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
FR2785293B1 (fr) | 1998-10-30 | 2002-07-05 | Pasteur Merieux Serums Vacc | Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
AU781598B2 (en) | 1999-04-21 | 2005-06-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibiting the function of polynucleotide sequences |
MXPA01011079A (es) | 1999-04-30 | 2002-07-22 | Univ Pennsylvania | Cd80 mutante de humano y composiciones y metodos para hacer y usar las mismas. |
ATE391726T1 (de) | 1999-10-22 | 2008-04-15 | Sanofi Pasteur Ltd | Modifiziertes gp100 und dessen verwendung |
AU781724B2 (en) | 1999-12-22 | 2005-06-09 | Trustees Of The University Of Pennsylvania, The | Cosmid DNA constructs and methods of making and using the same |
EP1254212A2 (en) | 2000-02-09 | 2002-11-06 | Genvec, Inc. | Methods of preparing and using a viral vector library |
EP2011889B1 (en) | 2000-04-18 | 2011-09-28 | Virco BVBA | Methods for measuring drug resistance against HCV |
EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
EP1741782B1 (en) | 2000-05-10 | 2011-06-22 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
EP1311289B1 (en) | 2000-08-17 | 2007-10-17 | Tripep Ab | Vaccines containing ribavirin |
US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
RU2286172C2 (ru) | 2000-08-17 | 2006-10-27 | Трипеп Аб | Вакцины, содержащие рибавирин, и способы их использования |
EP1313771B1 (en) | 2000-08-25 | 2007-03-21 | Aventis Pasteur Limited | Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections |
MXPA03006421A (es) | 2001-01-22 | 2004-12-02 | Hoffmann La Roche | Dispositivo de lanceta que tiene accion capilar. |
WO2002100317A2 (en) | 2001-05-25 | 2002-12-19 | The Trustees Of The University Of Pennsylvania | Targeted particles and methods of using the same |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
EP1285971B1 (en) * | 2001-08-08 | 2007-10-10 | Tibotec Pharmaceuticals Ltd. | Methods for the phenotypic and genotypic assessment of the drug sensitivity of HIV integrase variants |
DE10142232B4 (de) | 2001-08-29 | 2021-04-29 | Roche Diabetes Care Gmbh | Verfahren zur Herstellung eines analytischen Hilfsmittels mit Lanzette und Testelement |
US7462491B2 (en) | 2002-01-31 | 2008-12-09 | Baylor College Of Medicine | Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin |
CN100593544C (zh) | 2002-03-15 | 2010-03-10 | 惠氏控股有限公司 | 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体 |
EP1356820A1 (en) | 2002-04-26 | 2003-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | DNA vaccine combined with an inducer of tumor cell apoptosis |
US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
WO2004000217A2 (en) | 2002-06-20 | 2003-12-31 | The Trustees Of The University Of Pennsylvania | Vaccines for suppressing ige-mediated allergic disease and methods for using the same |
ATE544466T1 (de) | 2002-10-29 | 2012-02-15 | Coley Pharm Group Inc | Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion |
NZ540152A (en) | 2002-11-19 | 2008-03-28 | Univ Pennsylvania | Genetic constructs and compositions comprising RRE and CTE and uses thereof |
NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
CA2529051A1 (en) | 2003-06-13 | 2004-12-29 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
CA2547635C (en) | 2003-12-12 | 2016-02-09 | Jeffrey Schlom | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
AU2005333603A1 (en) | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens |
US20080274140A1 (en) | 2004-11-19 | 2008-11-06 | David B Weiner | Vaccines and Methods for Using the Same |
CA2636867C (en) | 2006-01-13 | 2015-12-01 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same |
WO2007082105A2 (en) | 2006-01-16 | 2007-07-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chlamydia vaccine |
WO2007109583A2 (en) | 2006-03-17 | 2007-09-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
KR102334637B1 (ko) | 2006-07-28 | 2021-12-06 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 및 이의 사용 방법 |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
CN101877965B (zh) | 2007-11-12 | 2014-08-20 | 宾夕法尼亚大学托管会 | 针对流感病毒的多种亚型的疫苗 |
JP2011504173A (ja) | 2007-11-14 | 2011-02-03 | ブイジーエックス ファーマシューティカルズ,リミティド ライアビリティー カンパニー | 電気穿孔により送達されるdnaワクチンにより誘導される抗体の産生 |
WO2010044919A2 (en) | 2008-05-28 | 2010-04-22 | Vgx Pharmaceuticals, Inc. | Smallpox dna vaccine and the antigens therein that elicit an immune response |
US8921536B2 (en) | 2008-10-29 | 2014-12-30 | The Trustees Of The University Of Pennsylvania | HCV vaccines and methods for using the same |
US8829174B2 (en) | 2008-10-29 | 2014-09-09 | The Trustees Of The University Of Pennsylvania | HCV vaccines and methods for using the same |
CN102292345B (zh) | 2008-11-17 | 2015-12-02 | Vgx药品有限责任公司 | 引起对抗黄病毒的免疫应答的抗原及其应用方法 |
CA2653478A1 (en) | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
US9050287B2 (en) | 2009-01-23 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
US9029135B2 (en) | 2009-03-27 | 2015-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Kanamycin antisense nucleic acid for the treatment of cancer |
KR20210149203A (ko) | 2009-11-02 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 구제역 바이러스(fmdv) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신 |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
JP6125232B2 (ja) | 2010-02-08 | 2017-05-10 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Rantesをコードする核酸分子、ならびにこれを含む組成物およびこれを用いる方法 |
KR20180096814A (ko) | 2010-09-27 | 2018-08-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법 |
BR112013011705B1 (pt) | 2010-11-12 | 2022-04-05 | The Trustees Of The University Of Pennsylvania | Antígenos de próstata de consenso, molécula de ácido nucleico quecodifica os mesmos e vacina e usos compreendendo os mesmos |
CN103827131B (zh) | 2011-01-31 | 2017-06-30 | 宾夕法尼亚大学托管会 | 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法 |
US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
HUE049669T2 (hu) | 2011-02-11 | 2020-10-28 | Univ Pennsylvania | Hepatitis B vírus magfehérjéjét kódoló nukleinsav-molekula és azt tartalmazó oltóanyag |
JP6143231B2 (ja) | 2011-06-10 | 2017-06-07 | ブルーバード バイオ, インコーポレイテッド | 副腎脳白質ジストロフィおよび副腎脊髄神経障害のための遺伝子療法ベクター |
ES2758713T3 (es) | 2011-07-11 | 2020-05-06 | Inovio Pharmaceuticals Inc | Vacuna de ADN contra el virus de Lassa |
AU2012352455B2 (en) | 2011-12-12 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections |
BR112014014078A8 (pt) | 2011-12-12 | 2021-09-28 | Univ Pennsylvania | Composições compreendendo constructos genéticos il-12 aperfeiçoados e vacinas, imunoterapêuticos e métodos de usar os mesmos |
EP3511337A1 (en) | 2012-04-10 | 2019-07-17 | The Trustees of The University of Pennsylvania | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same |
WO2013155441A1 (en) | 2012-04-12 | 2013-10-17 | The Trustees Of The University Of Pennsylvania | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
US9738879B2 (en) | 2012-04-27 | 2017-08-22 | Duke University | Genetic correction of mutated genes |
WO2014093897A1 (en) | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Wt1 vaccine |
WO2015089492A2 (en) | 2013-12-13 | 2015-06-18 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
CN114181961A (zh) | 2013-03-12 | 2022-03-15 | 宾夕法尼亚大学理事会 | 用于人***状瘤病毒的改进疫苗及其使用方法 |
CN114045295A (zh) | 2013-03-15 | 2022-02-15 | 宾夕法尼亚大学理事会 | ***病毒(fmdv)共有蛋白、其编码序列以及由其制造的疫苗 |
JP6769865B2 (ja) | 2013-03-15 | 2020-10-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ガンワクチン及びそれを用いた治療方法 |
US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
CN114230675A (zh) | 2013-06-05 | 2022-03-25 | 杜克大学 | Rna指导的基因编辑和基因调节 |
EP4176897A1 (en) | 2013-06-25 | 2023-05-10 | International AIDS Vaccine Initiative, Inc. | Tuberculosis compositions and methods of using the same |
EP3169699A4 (en) | 2014-07-18 | 2018-06-20 | The University of Washington | Cancer vaccine compositions and methods of use thereof |
US11319555B2 (en) | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
JP7268958B2 (ja) | 2014-12-01 | 2023-05-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Dna抗体構築物及びその使用方法 |
US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
WO2016179034A2 (en) | 2015-05-01 | 2016-11-10 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs |
EP3325018A4 (en) | 2015-07-22 | 2019-04-24 | Duke University | HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES |
IL288662B2 (en) | 2015-08-25 | 2023-09-01 | Univ Duke | Preparations and methods for improving specificity in genomic engineering using RNA-guided endonucleases |
US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
WO2017082946A1 (en) | 2015-11-13 | 2017-05-18 | University Of Utah Research Foundation | Combinatorial gene construct and non-viral delivery for anti-obesity |
CN118147141A (zh) | 2015-11-30 | 2024-06-07 | 杜克大学 | 用于通过基因编辑修正人肌营养不良蛋白基因的治疗靶标和使用方法 |
EP3411122A4 (en) | 2016-02-05 | 2019-10-23 | Inovio Pharmaceuticals, Inc. | CANCER VACCINES AND TREATMENT METHODS THEREWITH |
EP3452498B1 (en) | 2016-05-05 | 2023-07-05 | Duke University | Crispr/cas-related compositions for treating duchenne muscular dystrophy |
CA3027995A1 (en) | 2016-06-16 | 2017-12-21 | Aeras | Tuberculosis compositions and methods of treating or preventing tuberculosis |
US11091775B2 (en) | 2016-06-22 | 2021-08-17 | Oregon Health And Science University | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Cpf1に基づくゲノム編集の治療適用 |
WO2018081504A1 (en) | 2016-10-28 | 2018-05-03 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus |
EP3697806A4 (en) | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | TUBERCULOSIS ANTIGEN CASSETTES |
AU2018383662C1 (en) | 2017-12-13 | 2023-02-09 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting MUC16 and uses thereof |
BR112020011443A2 (pt) | 2017-12-13 | 2020-12-01 | Inovio Pharmaceuticals, Inc. | molécula de ácido nucleico e seu uso, vetor e seu uso, composição, proteína e vacina |
WO2019118760A1 (en) | 2017-12-13 | 2019-06-20 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting mesothelin and uses thereof |
IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
CN115175921A (zh) | 2019-12-06 | 2022-10-11 | 斯克里贝治疗公司 | 颗粒递送*** |
WO2022261149A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
WO2023227669A2 (en) | 2022-05-26 | 2023-11-30 | UCB Biopharma SRL | Novel nucleic acid-editing proteins |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3688765A (en) | 1969-10-03 | 1972-09-05 | Jack S Gasaway | Hypodermic injection device |
GB1594097A (en) | 1976-12-16 | 1981-07-30 | Int Inst Of Differentiation | Production of specific immune nucleic acids cell dialysates and antibodies |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4680027A (en) | 1985-12-12 | 1987-07-14 | Injet Medical Products, Inc. | Needleless hypodermic injection device |
US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5024656A (en) | 1988-08-30 | 1991-06-18 | Injet Medical Products, Inc. | Gas-pressure-regulated needleless injection system |
US5185254A (en) | 1988-12-29 | 1993-02-09 | The Wistar Institute | Gene family of tumor-associated antigens |
JP3140757B2 (ja) | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥hivプロウイルス、細胞系及びその使用 |
ATE277193T1 (de) * | 1989-03-21 | 2004-10-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
WO1991007425A1 (en) | 1989-11-20 | 1991-05-30 | Oncogen Limited Partnership | Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens |
CA2071214C (en) * | 1989-12-21 | 2006-06-06 | Alan Frankel | Method of delivering molecules into eukaryotic cells |
AU7312891A (en) | 1990-02-12 | 1991-09-03 | Board Of Regents, The University Of Texas System | Satellite cell proliferation in adult skeletal muscle |
DK0584279T3 (da) * | 1991-05-14 | 2001-06-11 | Immune Response Corp Inc | Målrettet aflevering af gener, som koder for immunogene proteiner |
JP3881689B2 (ja) * | 1992-03-11 | 2007-02-14 | パウダージェクト ヴァクシンズ,インコーポレイテッド | 免疫不全ウイルス用の遺伝子ワクチン |
AU4253493A (en) | 1992-05-21 | 1993-12-13 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting gene expression to living tissue using jet injection |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
-
1994
- 1994-01-26 EP EP94909492A patent/EP0681483B1/en not_active Expired - Lifetime
- 1994-01-26 PT PT94909492T patent/PT681483E/pt unknown
- 1994-01-26 AU AU62320/94A patent/AU675702B2/en not_active Expired
- 1994-01-26 IL IL108449A patent/IL108449A/en not_active IP Right Cessation
- 1994-01-26 DE DE69434469T patent/DE69434469T2/de not_active Expired - Lifetime
- 1994-01-26 NZ NZ262582A patent/NZ262582A/en not_active IP Right Cessation
- 1994-01-26 JP JP51728594A patent/JP3701966B2/ja not_active Expired - Lifetime
- 1994-01-26 AT AT94909492T patent/ATE302854T1/de active
- 1994-01-26 ES ES94909492T patent/ES2249760T3/es not_active Expired - Lifetime
- 1994-01-26 DK DK94909492T patent/DK0681483T3/da active
- 1994-01-26 CA CA2153593A patent/CA2153593C/en not_active Expired - Lifetime
- 1994-01-26 WO PCT/US1994/000899 patent/WO1994016737A1/en active IP Right Grant
- 1994-01-26 HU HU9502229A patent/HU219767B/hu not_active IP Right Cessation
-
2005
- 2005-12-23 US US11/317,548 patent/US8304234B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU6232094A (en) | 1994-08-15 |
EP0681483A4 (en) | 1997-06-25 |
CA2153593C (en) | 2010-04-13 |
IL108449A0 (en) | 1994-04-12 |
US20060222629A1 (en) | 2006-10-05 |
NZ262582A (en) | 1997-10-24 |
WO1994016737A1 (en) | 1994-08-04 |
JP3701966B2 (ja) | 2005-10-05 |
EP0681483B1 (en) | 2005-08-24 |
IL108449A (en) | 2011-09-27 |
HUT73099A (en) | 1996-06-28 |
ATE302854T1 (de) | 2005-09-15 |
PT681483E (pt) | 2005-11-30 |
CA2153593A1 (en) | 1994-08-04 |
DE69434469T2 (de) | 2006-06-14 |
DE69434469D1 (de) | 2005-09-29 |
ES2249760T3 (es) | 2006-04-01 |
US8304234B2 (en) | 2012-11-06 |
EP0681483A1 (en) | 1995-11-15 |
AU675702B2 (en) | 1997-02-13 |
HU9502229D0 (en) | 1995-09-28 |
HU219767B (hu) | 2001-07-30 |
JPH08509694A (ja) | 1996-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0681483T3 (da) | Præparater og fremgangsmåder til administration af genetisk materiale | |
DK0772437T3 (da) | Sammensætninger til levering af genetisk materiale | |
EP0340793A3 (en) | Endowing cells with antibody specificity | |
WO1988009818A3 (en) | Growth hormone receptor | |
DE69332434T2 (de) | Clostridium perfringens Impfstoffe | |
AR003423A1 (es) | Anticuerpos monoclonales humanos de alta afinidad especificos de la proteina- f del rsv, celulas eucarioticas transfectadas; secuencia de adn y vector de expresion que lo codifican; metodo que utiliza los anticuerpos; una composicion farmaceutica que los contiene; metodo para detectar rsv y un kit de ensayo. | |
ATE270303T1 (de) | Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper | |
DE69939327D1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
ES2010727A6 (es) | Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv. | |
ATE293169T1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
DK1025236T3 (da) | Human checkpoint kinase, HCDS1, præparater og fremgangsmåde | |
Nygren et al. | 95-and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor. | |
Chin et al. | Selective associations of hormonal steroids with aminoacyl transfer RNAs and control of protein synthesis | |
DK1473369T3 (da) | Præparater og fremgangsmåde til administration af genetisk materiale | |
ATE266731T1 (de) | Neue menschliche proteine, die cyclin abhängigen kinasen ähneln, sowie methoden zu deren verwendung | |
Leserman | The introversion of the immune response: a hypothesis for TB interaction | |
FR2694938B1 (fr) | Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant. | |
RU2221873C2 (ru) | Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность |